{"entity":{"id":"nct06041061","kind":"trial","name":"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years","aka":[],"tldr":"A phase 3 trial of Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell） in advanced solid tumours, run by Sinocelltech Ltd., active and no longer recruiting.","summary":"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years is a phase 3 interventional study registered as NCT06041061 by Sinocelltech Ltd., with 18000 participants enrolled, started 2023-08-13 and due to reach its primary completion in 2024-03. Interventions recorded: Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell） and placebo.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06041061","url":"https://clinicaltrials.gov/study/NCT06041061"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["sinocelltech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06041061","phase":"3","setting":"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating the Efficacy, Safety, and Immunogenicity of a 14- Valent Recombinant Human Papillomavirus Vaccine (SCT1000) in Healthy Women Aged 18-45 Years","sponsor":"Sinocelltech Ltd.","enrolled":18000,"outcomes":[]},"route":"/trials/nct06041061/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"sinocelltech","kind":"company","name":"Sinocelltech","route":"/companies/sinocelltech/"}]}}